

## Freedom of Information Request: Our Reference CTHB\_154\_19

### You asked:

Within your health board how many **intra-vitreous injections/implants** have been used in the latest 4 months, if possible between January and April 2019. If your health board is able to identify **injections/implants** by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].

	Lucentis (Ranibizumab) Injections	Avastin (Bevacizumab) Injections	Eylea (Aflibercept) Injections	Iluvieb (Fluocinolone) Implants	Ozudex (Dexamethasone) Implants
<b>TOTAL</b>	607	9			
Wet Age Related Macular Degeneration (wAMD)	312		336		
Diabetic Macular Oedema (DMO)	182		104		6
Retinal Vein Occlusion – Central or Branch (CRVO or BRVO)	106		91		**
Other eg mCNV	7	9	**		5

In response to your recent request the table above has been populated with the number of injections administered during the period of 1<sup>st</sup> January and 30<sup>th</sup> April, 2019, by medicine and by diagnosed eye condition.

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.